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Abstract
Background: Several factors have been proposed to assess the clinical outcome of HCV infection. The correlation
of HCV genotypes to possible serum markers in clinical prediction is still controversial. The main objective of this
study was to determine the existence of any correlation between HCV genotypes to viral load and different clinical
serum markers.
Methods: We performed a prospective cross-sectional and observational study. About 3160 serum HCV RNA
positive patients were chosen from 4020 randomly selected anti-HCV positive patients. Statistical analysis was
performed using the SPSS 16 software package. ROC (receiver operating characteristics) curves were used to
compare diagnostic values of serum markers to predict genotypes.
Results: The most prevalent genotype was 3a (73.9%) followed by 1a (10.7%), 4a (6.4%) and 3b (6.1%) in Pakistani
population. No correlation was found between viral load and serum markers for genotype 3a in a large no. of
sample (n = 2336). While significant correlation was observed between viral load and AST in genotype 3b, ALP
with viral load and ALT for genotype 1a. Patients with genotype 4a showed a significant inverse correlation with
viral load and Hb level and AST with ALP. For genotype 4a, AUC (area under the curve) of ALT, ALP, AST, bilirubin,
Hb level and viral load was 0.790, 0.763, 0.454, 0.664, 0.458 and 0.872 respectively.
Conclusions: In conclusion, there was a significant variable response of HCV genotypes with serum markers.
Severity of disease is independent of serum marker level in genotype 3a, while the liver damage in genotype 4a
may associate with viral cytopathic effect as well as the immune-mediated process. An index using six serum
markers may correctly predict genotype 4a in patients with ≥75% accuracy.
Introduction
Hepatitis C virus (HCV) is a major cause of liver asso-
ciated diseases all over the world. An estimated 3% of
the world’s populations (more than 350 million people)
are chronically infected with HCV, which is the main
cause of liver fibrosis, cirrhosis and hepatocellular carci-
noma (HCC) in a substantial number of patients [1,2].
Due to considerable sequence diversity and sequence
comparisons in different parts of hepatitis C virus gen-
ome, classification of the virus into a series of genotypes
showed distinct geographical and frequency distribution
across the whole world [3-6].
Approximately, 10 million people in Pakistan are
infected with HCV [7]. It is well established factor that in
patients infected with HCV, the clinical findings, geno-
types and viral load are strong predictors for the outcome
of antiviral therapy [8,9]. The most prevalent genotype in
Pakistan is 3a followed by 3b and 1a [10]. Due to high
prevalence of genotype 3a in Pakistan; HCV genotyping
is not recommended for HCV infected patients routinely
by Pakistan’s Society of Gastroenterology [11]. Secondly,
due to poverty and cost of genotyping test, many patients
refused to do genotyping. Nevertheless, genotyping is
important because it not only provides information as to
strain variation and potential association with disease
severity but also related to the possibility of treatment
response, as the treatment plan of chronic HCV infection
with interferon varies with the genotype being treated
[12,13]. It is reported that treatment with interferon is
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any medium, provided the original work is properly cited.more effective in patients with genotypes 2 and 3 than in
patients infected with genotypes 1 and 4 [14,15]. Several
studies revealed that HCC develops in 1-4% of patients
and liver biopsy is considered the gold standard to iden-
tify liver fibrosis. Unfortunately, procedure of liver biopsy
is invasive, expensive and unsuitable for all patients with
severe side effects leading to death [1,11,15,16]. An
assessment of the disease development based on clinical
findings is still critical for patients infected with HCV. At
present, the clinicopathological significance of serum bio-
chemical markers and viral load and their relationship
among different genotypes is not well known. Several
authors tried to find accurate noninvasive markers of
liver damage and developed correlations between the
serum hyaluronic acid levels, collagen level, platelet
count, serum bilirubin levels, HCV viral load, genotypes
and elevated ALT/AST levels in HCV infected patients,
but no clear conclusions were formed [17-23].
In present study, we investigated the correlation of sev-
eral clinical findings like Hb level, bilirubin level, ALT,
ALP and AST and viral load in patients with different
genotypes. The ideal serum markers for genotype deter-
mination should have good sensitivity, be readily avail-
able, inexpensive, reproducible, safe and able to predict
genotypes with accuracy. The need of genotyping may be
eradicated if the serum biochemical markers with high
positive or negative predictive values of several genotypes
can be obtained and thus minimize the cost of genotyp-
ing and liver biopsy.
Materials and methods
Patients
Patients of this study were the people referred to Pathol-
ogy department, Jinnah Hospital, Lahore, Pakistan, for
biochemical and serological tests. This analytical study
was carried out from March 2007 to September 2009
with collaboration of National Centre of Excellence in
Molecular Biology, University of the Punjab, Lahore,
Pakistan. Blood samples (10 mL) were collected from
each patient and tested for anti-HCV antibody by ELISA.
Adult (≥18 years) patients with positive serology and/or
positive test for HCV alone and no evidence of liver fail-
ure were included in this study. Patients who were not
keen to give informed consent, not able to make follow-
up visits and not willing to undergo genetic testing and
allow samples to be stored for future research were
excluded from the study. Accordingly, thus, 3160 HCV-
RNA positive patients from 4020 HCV antibody (anti-
HCV)-positive persons were identified. Questioner
(including their personal, lab tests and demographical
information, possible transmission route of HCV infec-
tion, clinical, virological and biochemical data) was pre-
pared for patients who came for HCV initial screening
and further genotyping and viral load quantification. The
routine liver function tests (LFTs), Hb level and direct
bilirubin were estimated for each patient in the hospital
laboratory. Informed consent was obtained from patients.
The study was approved by the institutional ethical
committee.
HCV antibody and viral assays
HCV detection and genotyping was performed at the
Department of Pathology, Jinnah Hospital, Lahore, Paki-
stan. RNA was extracted from 140µl of serum samples
using QIAamp viral RNA extraction kit (Qiagen, USA)
according to the manufacturer’s protocol. cDNA was
synthesized using Moloney murine leukemia virus
(MmLV) followed by PCR using primers derived from the
5’UTR non-coding region of HCV genome described by
Chan et al. [24]. For HCV RNA quantification, Qiagen
HCV RG RT-PCR assay was used. Quantification was car-
ried out with 10 ul of the extracted RNA on Rotor-gene
Real-Time PCR machine (USA) using fluorescent probes
to detect amplification after each replicating cycle as
described by manufacturer protocol. The lower limit of
detection for this assay is 1000 IU/ml HCV and genotyp-
ing was carried out using Invader HCV genotyping assay
(Third wave technology, USA). Briefly, 100 ng of the HCV
RNA was reverse transcribed to cDNA using 200 U of
MmLV (Invitrogen, USA). From the amplified product,
2µl were taken and the genotyping assay was performed
for 12 different HCV types.
Statistical analysis
Statistical analysis was performed using the statistical
package for social studies (SPSS) version 16 for windows.
Student t-test and Chi-square tests were applied to evalu-
ate differences in proportions. P value <0.05 was consid-
ered significant. Univariate analysis includes the variables
age, sex, Hb level, bilirubin, ALT, AST, ALP and viral
load. Age, sex and genotypes were taken as independent
categorical factors. The normal values of ALT, ALP, AST
and direct bilirubin level were (~5-40 IU/ mL), (< 120
IU/ mL), (~10-40 IU/ mL) and (< 0.4 mg/ dl) respec-
tively. Multiple regression analysis was used to evaluate
independent associations between HCV genotypes and
individual demographic characteristics and biochemical
values to identify variables association within different
genotypes. Once we determined that differences exist
among the means, post hoc range tests and pair-wise
multiple comparisons were determined. Comparisons
were made on unadjusted values fixed between-patients
factors only. The relationship between serum markers
and genotypes were analyzed by Spearman’s correlation
f o rn o n - p a r a m e t r i cd a t aa n db yt h eP e a r s o nm e t h o df o r
parametric data. To obtain cutoff values of serum mar-
kers for HCV genotypes, receiver operating characteris-
tics (ROC) curves were drawn for serum markers by
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(1-specificity [25]. Comparison of the area under the
curve (AUC) was used to assess the overall diagnostic
values of serum markers.
Results
Prevalence of HCV infection
Of the 4020 ELISA positive patients, 3160 (78.6%) showed
positive PCR while 860 (21.4%) were negative for HCV.
Out of 3160 patients with positive PCR, 1515 (48%) were
males while 1645 (52%) were females. The median age of
patients was 37 years (range 18-75). Age of the patients
was taken as a continuous as well as a categorical variable.
Patients were divided into two age groups i.e. ≤ 40 years
and >40 years. In age group ≤ 40 years there were 2119
patient, while age group >40 years include 1041 patients.
Genotype distribution among patients
Based on weighted analysis of patients infected with
HCV, the most frequently detected genotype was 3
(80%), with predominant subtype 3a (73.9%) and 3b
(6.1%). Genotype 1 (10.7%) was exclusively consisted of
the subtype 1a, while genotype 4 (7.1%) comprised the
subtype a (6.4%) and b (0.7%). Patients with mix geno-
type 4 &5 (0.8%) and untypable genotype 1(0.2%) were
also identified. The genotype 2b was detected in only
three (0.1%) patients. The frequency distribution of dif-
ferent genotypes according to age groups and gender is
given in Table 1. Distribution of genotypes among age
groups was not statistically different (p = 0.488). Geno-
t y p es u b t y p e3 aw a st h em o s tp r e v a l e n tg e n o t y p ei n
both age groups followed by 1a. Only three patients
(0.14%) with genotype 2b were observed in age group
≤ 40 years. Overall prevalence of genotypes within gen-
der was also statistically non-significant (p = 0.098).
Association of age, gender and genotypes with serum
markers and viral load
Univariate analysis (Table 2) revealed that all serum mar-
kers were independently distributed between gender and
age groups while serum markers including direct bilirubin
level, serum ALP and ALT levels and viral load were sig-
nificantly different among genotypes. Box plots of the
above four significant serum markers with eight different
HCV genotypes are shown in Figure 1. The overall mean
bilirubin value was 0.74 ± 0.18 mg/dL. The bilirubin level
was high in genotype 2b (0.80 ± 0.10), 4a (0.81 ± 0.05), 4b
(0.90 ± 0.12), 4&5 (0.89 ± 0.003) and untypable (0.88 ±
0.09) while genotype 1a (0.706 ± 0.14) and 3a (0.735 ±
0.20) showed a low bilirubin level. Serum ALP levels
(mean 209.03 ± 64 IU/mL) were higher in genotype
1a (251 ± 62.2), 2b (287 ± 36.37), 3b (221.1 ± 70.1), 4a
(275.7 ± 70.5), 4b (227.2 ± 72.1), 4&5 (232.7 ± 63.1) and
untypable (315.1 ± 54.1) in comparison to genotype 3a
(193.9 ± 54.3). Serum levels of ALT (mean value 71.1 ±
35.06 IU/mL) were significantly elevated in 2b (105 ±
9.64) and 4a (108.1 ± 35.6) genotypes as compared to 1a
(72.1 ± 36.5), 3a (67.6 ± 32.9), 3b (72.6 ± 35.6), 4b (75.6 ±
31.3) and mix genotype 4&5 (74.4 ± 37.02), while serum
ALT levels were significantly low in patients with untyp-
able genotype (57.65 ± 23.5). Viral load varied from 1.1 ×
10
3 IU/mL to 8.5 × 10
8 IU/mL (mean, 6.8 × 10
7 ±1 . 2×
10
8). The viral load was significantly higher in genotype 2b
(1.5 × 10
7 ±2 . 3×1 0
7) and 4a (2.1 × 10
7 ±1 . 1×1 0
7) while
the patients with genotype 1a (4.5 × 10
6 ±9 . 8×1 0
6), 3a
(5.9 × 10
6 ± 1.1 × 10
7), 3b (7.1 × 10
6 ±1 . 1×1 0
7), 4b (1.9
×1 0
6 ±3 . 1×1 0
6) ,4 & 5( 6 . 7×1 0
6 ±1 . 1×1 0
7) and untype-
able (8.1 × 10
6 ±1 . 1×1 0
7) showed intermediate viremia
levels. Genotype 2b, 4b, mix and untypable were elimi-
nated from further analysis because of small sample size.
Further Multivariate analysis in Table 3 revealed that
Table 1 Genotype-specific representation according to gender and age
Genotypes
Characteristics 1 2 3 4 Mix Untypable
1a 2b 3a 3b 4a 4b 4&5 N.T
Total (n = 3160) 339
(10.7%)
3
(0.09%)
2336
(73.9%)
194
(6.1%)
202
(6.4%)
22
(0.69%)
26
(0.82%)
38
(1.2%)
Mean Age (SD) 36.3
(9.63)
36.67
(2.8)
37.39
(10.42)
36.19
(10.62)
37.01
(10.24)
32.45
(9.5)
33.46
(9.7)
35.42
(9.7)
Age Range (years) 18-66 35-40 18-75 18-74 18-70 18-55 18-51 18-50
Age Groups (years)
≤40 (n = 2119) 242 3 1534 140 136 18 21 25
≥ 40 (n = 1041) 97 0 802 54 66 4 5 13
Sex
Male (n = 1515) 152 0 1117 111 95 11 9 20
Female (n = 1645) 187 3 1219 83 107 11 17 18
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different among genotypes 1a, 3a, 3b and 4a.
Correlation of Significant Serum Markers and Viral load
within HCV genotypes
A correlation of significant serum markers with each
other and viral load in HCV infected patients is illu-
strated in Figure 2 showed that viral load has positive
correlation with ALP in genotype 1a (r =0 . 1 1 8 ,p =
0.030), linear significant correlation of viral load and
AST was found in 3b (r = -0.157, p =0 . 0 2 9 ) ,w h i l e
negative linear correlation of Hb level with viral load in
genotype 4a, was observed (r = -0.169, p =0 . 0 1 6 ) .
Regarding relationship between clinical factors, we
observed significant correlations between ALP and ALT
(r = -0.214, p = 0.000) in genotype 1a (Figure 3), ALT
and AST (r =0 . 0 4 2 ,p = 0.043) and ALP and ALT (r =
-0.046, p = 0.027) in genotype 3a, and AST and ALP
(r = -0.175, p = 0.013) in genotype 4a.
Determination of cutoff values of serum markers to
predict genotypes
ROC curves (Figure 4) to predict genotypes among
patients were plotted against serum markers and we
were able to found best cutoff points for genotype 4a.
The best cutoff values calculated to predict genotype 4a
were as: Hb level ≤ 11.85 g/dL, bilirubin level ≥ 0.75
mg/ dL, ALP level ≥ 243 IU/ mL, ALT≥ 125 IU/ mL,
AST level ~ 40-75 IU/ mL and serum viral load ≥ 1×
10
7 IU/mL. The cut off values with significant positive
predictive values (PPV) and negative predictive values
(NPV) and specificity and sensitivity for genotypes 4a
are given in Table 4. ALT, ALP, viral load and bilirubin
levels showed high PPV and NPV as compared to AST
and Hb level. Moreover, during evaluation the area
under the curve (AUC) of each serum marker as illu-
strated in Table 5 we observed high AUC for ALP 0.763
(95% Cl 0.724-0.801, p = 0.000), ALT 0.790 (95% Cl
0.756-0.824, p = 0.000) and viral load 0.872 (95% Cl
0.854-0.890, p = 0.000) while bilirubin level 0.664 (95%
Cl 0.641-0.0.686, p = 0.000), AST 0.454 (95% Cl 0.414-
0.494, p = 0.028) and Hb level 0.458 (95% Cl 0.418-
0.497, p = 0.045) showed moderate AUC.
Discussion
The difference in distribution of HCV genotypes sug-
gests the subsistence of diverse form of disease acquire-
ment. The basic aim of this study was to evaluate the
predictive value of a combination of basic serum bio-
chemical markers for the diagnosis of genotypes and
their relation to disease outcome.
The present study was conducted in randomly
selected samples of general population in Pakistan
(Table 1). Our patient’s data showed no significant dif-
ferences in genotype distribution in relation to gender
and age groups. Various genotypes, particularly 1, 3 and
4 were equally distributed in gender and age groups.
Prevalence of genotype in our study was: genotype 3 (n
= 2530, 80%), followed by genotype 1 (n = 339, 10.8%)
and genotype 4 (n = 224, 7.08%). Subtypes 3a, 1a and 4a
were predominant, whereas mix subtype 4a/5a was also
found in some patients (n = 26, 0.8%). Among patients,
1.2% (n = 38) showed untypable genotype.
The correlation among HCV genotypes with viral load
and serum markers and their association with disease
severity and sensitivity to interferon treatment remains
controversial till date [26,27]. Evaluating the correlation
between different clinical markers with genotypes, our
results showed that a combination of four clinical mar-
kers (ALT, AST, ALP and bilirubin level) and serum
viral load can have high positive or negative predictive
value for diagnosis of different HCV genotypes. Our
data showed significant increase in bilirubin levels in
patients with genotypes 4, mix (4&5) and untypable.
High bilirubin level is usually associated with liver
metastases and liver tumor involvement leading to hepa-
tocellular carcinoma and liver cirrhosis by active or non-
active HCV or HBV [28]. As different genotypes lead to
diverse severity levels of liver disease so the treatment
plan of chronic HCV infection with interferon varies
Table 2 Univariate analysis of patient’s data by age, sex
and genotype
Factors
Studied
Serum
Markers
95% Confidence
Interval
F-value p-value
Lower
Bound
Upper
Bound
AGE Hb level 12.800 12.986 1.759 .134
Bilirubin
level
.735 .753 .308 .873
ALP 204.201 210.449 1.007 .402
ALT 68.395 71.810 1.056 .377
AST 66.299 69.655 1.017 .397
Viral load 6409.094 7578.840 .698 .593
GENDER Hb level 12.783 12.916 2.537 .111
Bilirubin
level
.739 .752 .164 .686
ALP 206.795 211.275 .004 .952
ALT 69.798 72.246 2.380 .123
AST 66.695 69.101 .730 .393
Viral load 6425.361 7263.954 .021 .886
GENOTYPE Hb level 12.361 12.996 1.295 .248
Bilirubin
level
.787 .847 17.846 .000
ALP 240.926 260.033 108.589 .000
ALT 73.576 84.729 39.728 .000
AST 63.472 74.892 1.070 .380
Viral load 6944.945 10731.895 48.110 .000
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used as marker of liver injury and to determine the
proper dose of interferon in patients with different gen-
otypes. Elevated aminotransferases levels act as indica-
tors of liver cell injury and are usually predominant in
liver cirrhosis with increased ALT levels [20,30]. We
o b s e r v e de l e v a t e dA L Ta n dA S Tl e v e l si na l lg e n o t y p e s
compared to normal range but in patients infected with
genotype 4a values were quite higher (>2 times to nor-
mal range 5-40 IU/ mL). These results could lead to the
confirmation association of genotype 4a with increased
risk of cirrhosis [31]. In previous studies, serum ALP
levels were not considered valuable markers during
HCV diagnosis but recent studies revealed that the
higher levels of ALP are usually associated with liver
metastasis, extraheptic bile obstruction, primary biliary
cirrhosis, intraheptic cholestasis, infiltrative liver disease,
hepatitis, cirrhosis, primary sclerosisng cholangitis, hepa-
tic lymphoma, liver abscess, sarcoidosis and congestive
cardiac failure [31-33]. A change in ALP levels greater
Figure 1 Variation of significant serum markers among genotypes. Box plots of four significant serum markers i.e. viral load, bilirubin level,
Serum ALP and ALT in relation with eight different HCV genotypes. The line through the middle of the box is the median while the top and
bottom of the box are 25
th and 75
th percentiles.
Table 3 Multivariate analysis of significant serum
markers among genotypes 1a, 3a, 3b and 4a
Serum
Markers
Genotypes 95% Confidence
Interval
Hypothesis Test
Lower Upper Wald Chi-
Square
Sig.
Bilirubin
level
1a -.262 -.117 26.314 0.000
3a -.231 -.091 20.225 0.000
4a -.250 -.099 20.463 0.000
ALP 1a 17.962 18.760 8140.621 0.000
3a -61.075 -16.561 11.685 0.001
4a 42.554 43.371 42517.226 0.000
ALT 1a -2.660 -1.862 123.417 0.000
3a -7.100 -6.327 1159.056 0.000
4a 33.247 34.063 26090.882 0.000
Viral load 1a -2221.812 -2221.014 1.192E8 0.000
3a -771.541 -770.768 1.529E7 0.000
3b 454.651 455.470 4.747E6 0.000
4a 14092.652 14093.469 4.575E9 0.000
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gression [34]. In our study patients with genotype 4a
reflected high ALP levels as compared to others as illu-
strated in Figure 1.
Patients infected with genotype 3a showed negative
correlation between ALP and ALT while a positive
correlation was also found between AST and ALT in
patients infected with genotype 3a. No correlation
between serum viremia levels and other serum markers
in genotype 3a in our study was in agreement with out-
come of Azzari et al and Abraham et al that the viral
load was independent of ALT activity in HCV [18,35].
Figure 2 Correlation of serum markers with each other in HCV genotypes. Significant correlation between different serum markers in
genotypes 1a, 3a, 3b and 4a was found. This can lead to different possible mechanisms of liver injury in different genotypes.
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RNA levels and amount of virus in liver or serum HCV
RNA levels and liver injury and vice versa in many stu-
dies. The involvement of different factors like different
clinico-histopathological evaluation procedures [2,16]
can lead to the opinion that liver injury in HCV infec-
tion due to genotype 3a is not directly associated with
serum viremia levels or the number of infected hepato-
cytes. Zechini et al found a relation between HCV viral
load and AST. However, we observed a negative correla-
tion between viral load and AST in genotype 3b that
may be due to poor immune response resulting in lower
AST level and higher viral load and vise versa lead to
liver damage [19,36].
In patients infected due to genotype 1a, viral load
showed significant positive correlation with ALP, and
ALP with ALT. Serum ALT and ALP can be used for
assessing the liver function status in anti-HCV positive
patients [37]. As elevated levels of ALP, ALT and AST
are associated with liver injury leading to cirrhosis, HCV
infection with genotype 1a could lead to more severe
liver damage as compared to genotype 3.
In our study patients infected with genotype 4a
showed high serum viral loads as compared to others,
while an inverse correlation between viral load and Hb
level and serum AST and ALP levels in genotype 4a was
also observed. Kato et al monitored significantly higher
HCV RNA level in patients with chronic active hepatitis
and cirrhosis compared to chronic persistent hepatitis
[38]. As HCV is associated with many extra hepatic
complications involving renal, articular, neuorologic,
cutaneous and haemopoietic systems, several autoim-
mune phenomenon are observed in patients infected
with HCV [39,40], decline of Hb level with increase of
viral load in genotype 4 may lead to autoimmune hae-
molytic anemia (AIHA) that can contribute to enhance
the liver cirrhosis in genotype 4 as the patients with
HCV related AIHA have higher prevalence of cirrhosis
Figure 3 Association of ALP and ALT in HCV genotype 1a.A
negative significant correlation was observed between ALP and ALT
in patients with genotype 1a.
Figure 4 Receiver operator characteristic (ROC) curves of six
serum markers. ROC curves were drawn to evaluate best cutoff
points for predicting genotypes. ROC curves of serum markers in
patients showed that viral load, ALP, ALT and bilirubin level can
better predict genotype 4a at given cutoff values.
Table 4 Sensitivity, specificity, and cutoff values of the
six serum markers to predict genotype 4a
SERUM
MARKERS
Cutoff values Sensitivity Specificity PPV
(%)
NPV
(%)
Hb level 11.85 g/dL 60 37 65 44
Bilirubin
level
0.75 mg/ dL 96 53 96 60
ALP 243 IU/ mL 81 62 82 78
ALT 125 IU/ mL 62 89 62 96
AST ~ 40-75 IU/ mL 51 45 65 64
Viral load 1×1 0
7 IU/ mL 75 82 77 86
Table 5 AUROC analysis of serum markers for predicting
genotype 4a in chronic HCV patients
Serum
Marker
Area Std.
Error
Significance 95% Confidence
Interval
Lower
Bound
Upper
Bound
Hb level 0.458 0.020 0.045 0.418 0.497
Bilirubin
level
0.664 0.011 0.000 0.641 0.686
ALP 0.763 0.020 0.000 0.724 0.801
ALT 0.790 0.017 0.000 0.756 0.824
AST 0.454 0.020 0.028 0.414 0.494
Viral load 0.872 0.009 0.000 0.854 0.890
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in AST levels in patients with genotype 4a may lead to
cholestatic hepatitis that is a severe form of HCV recur-
rence after treatment and organ transplantation like
liver, kidney and heart [42,43].
Based on our findings, we calculated the optimum cut-
off values of serum markers by generating ROC curves to
predict HCV genotypes in HCV-RNA positive patients.
To assess the diagnostic accuracy of serum markers to
evaluate patients require the selection of a decision
threshold. As, both sensitivity and specificity are equally
important in classifying patients with positive PCR for
genotypes, we were able to find the best cutoff values of
each serum marker for genotype 4a that can maximize
the sum of sensitivity and specificity as illustrated in
Table 4. At given cutoff values for each serum marker in
patients infected with genotype 4a, 60% have raised ALT
≥ 125 IU/ mL, 82.5% have elevated ALP ≥ 243 IU/ mL,
99.5% have bilirubin level more than ≥ 0.8 mg/ dL and
95% with raised serum viremia levels up to ≥ 1×1 0
7 IU/
mL, 75.2% have low Hb level (≤ 11.85g/ dL) and 65%
showed mild increase in AST levels (40~75 IU/ mL). The
percentage accuracy of each serum marker at given cutoff
values is; Hb level 58%, bilirubin level 73.2%, ALP 70.3%,
ALT 86.5%, AST 44.6% and viral load 84.6%. These all
serum markers in combination may predict genotype 4a
in patients with more than 75% accuracy.
I nP a k i s t a nd u et op o v e r t y ,d o c t o r su s u a l l yd on o t
recommend the genotype testing, as they consider HCV
3a more prevalent and INF therapy responder, but due to
high frequency of genotype 1a and 4a and for better dose
administration, time course of INF therapy and sustainable
response, importance of genotyping cannot be neglected.
It is conceivable that serum viral load, ALT, ALP and bilir-
ubin levels are suitable factors that may determine liver
damage as well as HCV genotypes. Although all genotypes
showed significant variable response to the serum markers,
we were able to find serum markers with viral load that
can predict genotype 4a, with more than 75% accuracy.
However we recommend genotyping assay to find possible
association with disease severity and guide about treat-
ment duration and outcomes. Future studies are required
in liver biopsy samples to confirm the association we
found in this study.
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